These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 33170349)

  • 21. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis.
    Aquaro GD; Pugliese NR; Perfetto F; Cappelli F; Barison A; Masci PG; Passino C; Emdin M
    Int J Cardiovasc Imaging; 2014 Aug; 30(6):1105-15. PubMed ID: 24789582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
    Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
    J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.
    Hu M; Song Y; Yang C; Wang J; Zhu W; Kan A; Yang P; Dai J; Yu H; Gong L
    Sci Rep; 2024 Jul; 14(1):16832. PubMed ID: 39039146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
    Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
    Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
    Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
    JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of cardiac magnetic resonance imaging and myocardial biopsy in the evaluation of nonischemic cardiomyopathy.
    Dickerson JA; Raman SV; Baker PM; Leier CV
    Congest Heart Fail; 2013; 19(1):29-38. PubMed ID: 22963032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis.
    Pozo E; Kanwar A; Deochand R; Castellano JM; Naib T; Pazos-López P; Osman K; Cham M; Narula J; Fuster V; Sanz J
    Heart; 2014 Nov; 100(21):1688-95. PubMed ID: 25012950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging.
    Gotschy A; von Deuster C; van Gorkum RJH; Gastl M; Vintschger E; Schwotzer R; Flammer AJ; Manka R; Stoeck CT; Kozerke S
    J Cardiovasc Magn Reson; 2019 Sep; 21(1):56. PubMed ID: 31484544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis.
    Bhatti S; Watts E; Syed F; Vallurupalli S; Pandey T; Jambekar K; Mazur W; Hakeem A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):970-7. PubMed ID: 27225804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis.
    Fikrle M; Palecek T; Masek M; Kuchynka P; Straub J; Spicka I; Rysava R; Linhart A
    Clin Physiol Funct Imaging; 2016 May; 36(3):218-24. PubMed ID: 25393773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.
    Liu Y; Zhu J; Chen M; Wang L; Zhu M; Weng Z; Hu C
    Ann Transl Med; 2022 Jul; 10(14):794. PubMed ID: 35965812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional Amyloid Burden Differences Evaluated Using Quantitative Cardiac MRI in Patients with Cardiac Amyloidosis.
    Kim JY; Hong YJ; Han K; Lee HJ; Hur J; Kim YJ; Choi BW
    Korean J Radiol; 2021 Jun; 22(6):880-889. PubMed ID: 33686816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR.
    Kuetting DL; Homsi R; Sprinkart AM; Luetkens J; Thomas DK; Schild HH; Dabir D
    Int J Cardiol; 2017 Apr; 232():336-341. PubMed ID: 28153537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance.
    Yilmaz A; Kindermann I; Kindermann M; Mahfoud F; Ukena C; Athanasiadis A; Hill S; Mahrholdt H; Voehringer M; Schieber M; Klingel K; Kandolf R; Böhm M; Sechtem U
    Circulation; 2010 Aug; 122(9):900-9. PubMed ID: 20713901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging.
    Florian A; Ludwig A; Rösch S; Yildiz H; Sechtem U; Yilmaz A
    Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):1004-12. PubMed ID: 24686257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].
    Cui Q; Yu J; Shen W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1538-1541. PubMed ID: 32029045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-gadolinium enhancement is common in older pediatric heart transplant recipients and is associated with lower ejection fraction.
    Lawson AA; Watanabe K; Griffin L; Laternser C; Markl M; Rigsby CK; Sojka M; Robinson JD; Husain N
    J Cardiovasc Magn Reson; 2023 Nov; 25(1):61. PubMed ID: 37932797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.